<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881566</url>
  </required_header>
  <id_info>
    <org_study_id>PRESEPSIN_IMMUNODIFFICIENCY</org_study_id>
    <nct_id>NCT03881566</nct_id>
  </id_info>
  <brief_title>Presepsin as Detective Marker of Sepsis in Immunodeficiency ICU Patients</brief_title>
  <acronym>PREICU</acronym>
  <official_title>Study of Usefulness of Presepsin as Early Detective Marker of Sepsis in Immunodeficiency ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jongmin Lee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study to evaluate the diagnostic and prognostic value of presepsin
      in the critically-ill immunocompromise patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of the Plasma Presepsin Concentration for Discriminating Between immunocompetent and immunocompromised patients.</measure>
    <time_frame>up to 7 days</time_frame>
    <description>For the analysis, plasma presepsin levels on Day 0 will be used. Sepsis was made on Day 7 or day of discharge. ROC-AUC of presepsin for discriminating between immunocompromised and immunocompetent patients is compared to that of procalcitonin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival at ICU discharge or day 28 after enrollment</measure>
    <time_frame>28 days</time_frame>
    <description>For the analysis, we will evaluate the association between presepsin and survival at ICU discharge or day 28 after enrollment</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sepsis</condition>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Immunocompetent sepsis patients</arm_group_label>
    <description>Sepsis patients without HIV infection (all stages), neutropenia (neutrophil count &lt; 1 × 109/L), exposure to glucocorticoids (&gt; 0.5 mg/kg for &gt; 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunocompromised sepsis patients</arm_group_label>
    <description>Sepsis patients with HIV infection (all stages), neutropenia (neutrophil count &lt; 1 × 109/L), exposure to glucocorticoids (&gt; 0.5 mg/kg for &gt; 30 d) and/or immunosuppressive or cytotoxic medications, solid organ transplantation, allogeneic or autologous stem cell transplantation, hematological malignancy, or solid tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without sepsis</arm_group_label>
    <description>Patients who admitted intensive care unit without sepsis</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma, Blood serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with presentation to ICU with critical illness compatible with sepsis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥ 19 years

          -  Appropriate clinical data to enable classification into sepsis

          -  Written informed consent by the patient or legally authorized representative

          -  Critical illness consistent with sepsis, to be enrolled within 24 hours of
             presentation

        Exclusion Criteria:

          -  No informed consent

          -  A patient who is judged to be unable to make a voluntary decision by understanding
             information about this research due to cognitive vulnerability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jongmin Lee, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jongmin Lee, M.D.</last_name>
    <phone>82-10-6300-7128</phone>
    <email>dibs03@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongmin Lee, M.D.</last_name>
      <phone>82-10-6300-7128</phone>
      <email>dibs03@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 9, 2019</study_first_submitted>
  <study_first_submitted_qc>March 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Jongmin Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

